The present disclosure generally relates to methods, devices, and systems for determining an analyte concentration in a fluid sample. More particularly, the present disclosure relates to meters for determining an analyte concentration that allow the user to input personal information and store that information.
The quantitative determination of analytes in body fluids is of great importance in the diagnoses and maintenance of certain physiological abnormalities. For example, lactate, cholesterol, and bilirubin should be monitored in certain individuals. In addition, determining glucose in body fluids is important to diabetic individuals who must frequently check the glucose level in their body fluids to regulate the carbohydrate intake in their diets.
In one type of blood-glucose testing system, test sensors are used to test samples of blood. The results of such tests can be used to determine what, if any, insulin or other medication needs to be administered. Diabetic individuals often test their blood-glucose levels both pre-event and post-event via a blood-glucose meter. Such events may include meals, exercise, illness, tracking ketones in urine, and the like.
Some existing glucose meters allow an individual to store past glucose readings and other information associated with the reading, including, for example, the date and time. Often, it is important for the individual to store these readings for future reference. Physicians may review this stored information to assist in diagnosing and monitoring the health of their patients.
It has been found that auxiliary factors may influence the analyte concentration reading. For example, a user's emotional state at the time of providing the blood sample may impact blood-glucose level readings. In particular, the user may have blood-glucose measurements that are higher or lower than they may otherwise have on the same medication dosage based on whether the user is experiencing certain moods or emotions, such as extreme happiness, sadness, or depression at or near the time that the blood sample is analyzed. Such changes in the blood-glucose readings may be caused by emotional issues that can be found in all individuals and may be especially prominent in adolescents as well as individuals having emotional issues. Likewise, a user's changing physiological state at or near the time of providing the fluid sample may affect the analyte concentration reading. It is thus desirable to overcome such disadvantages in existing meters.
According to one aspect of the present disclosure, a meter is presented for determining the concentration of an analyte in a fluid sample. The meter includes a housing configured to receive a test sensor having the fluid sample, and a processor configured to determine analyte concentration information from the fluid sample. A memory is operatively coupled to the processor and configured to store the analyte concentration information. The meter also includes a display that is coupled to the housing. The display is configured to display the analyte concentration information and one or more iconic markers. Each of the iconic markers represents a respective state of the user. An input device is operatively coupled to the processor. The input device is configured to receive a user selection of at least one of the iconic markers. The user's selection is stored by the memory.
According to another aspect of the present disclosure, a method of determining a concentration of an analyte in a fluid sample is presented. The method includes: analyzing, via a meter, a fluid sample of a user from a test sensor; determining, via a processor, analyte concentration information of the fluid sample; displaying, via a display, one or more of a plurality of iconic markers, each of which represents a respective state of the user; receiving an input selection from the user for at least one of the displayed iconic markers corresponding to a state of the user; and storing the user selection and the analyte concentration information of the fluid sample in the memory.
According to another aspect of the present disclosure, a method of determining a concentration of an analyte in a fluid sample with a continuous monitoring system is presented. The method includes: extracting a plurality of fluid samples; analyzing at least one of the fluid samples via the continuous monitoring system; determining, via the processor, analyte concentration information of the fluid sample; displaying, via the display, one or more of a plurality of iconic markers, each of the which represents a respective state of the user; receiving an input selection from the user for at least one of the displayed iconic markers corresponding to a state of the user; and storing the user selection and the analyte concentration information of the fluid sample in the memory.
According to even yet another aspect of the present disclosure, a computer-readable storage media is encoded with instructions for directing a meter to perform one or more of the disclosed methods.
The above summary is not intended to represent each embodiment or every aspect of the present disclosure. Rather, the summary merely provides an exemplification of some of the novel features included herein. The above features and advantages, and other features and advantages of the present disclosure, will be readily apparent from the following detailed description of the embodiments and best modes for carrying out the present concepts when taken in connection with the accompanying drawings and appended claims.
While the invention is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail below. It should be understood, however, that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
Those of ordinary skill in the art will realize that the following description is illustrative only and is not intended to be in any way limiting. Other embodiments will readily suggest themselves to such skilled persons having the benefit of this disclosure. As such, elements and limitations that are disclosed, for example, in the Abstract, Summary, and Detailed Description sections, but not explicitly set forth in the claims, should not be incorporated into the claims, singly or collectively, by implication, inference or otherwise. Reference will now be made in detail to implementations of the exemplary embodiments as illustrated in the accompanying drawings. The same reference indicators will be used throughout the drawings and the following description to refer to the same or like items.
The present disclosure is directed to a display with iconic markers for use in a meter, instrument, or system that is adapted to determine the concentration of an analyte in a fluid sample. Data regarding the state of a patient, such as an emotional state and/or a physiological state, at or near the time when a fluid sample is taken can provide substantial information, and thus have significant value, to a physician or other treating health care professional who reviews the analyte readings and notices changes over a period of time. For example, studies have revealed an association between psychosocial factors and the prognosis of both type 1 and type 2 diabetes. Considering that a patient logbook may only provide limited information and that patients often forget to record their blood glucose measurements and other information, physicians can utilize information of the patient's emotional well-being to make more informed decisions on a treatment plan if the physician has information of the patient's state at or near the time when the glucose readings were taken. For example, patients, such as adolescents, may experience a wide range of different moods and emotions over a given time, whereby the glucose readings may correspondingly vary or be irregular over that given period of time. Information of the patient's emotions over that period of time may provide important data to the physician in determining whether or not to responsively change the dosage of medication, change the dosing regimen, and/or prescribe additional medicine. For example, a physician seeing several high glucose readings may decide not to increase the insulin dose if the physician is presented with information that the patient was undergoing distress when those readings were taken.
Studies have also shown an association between physiological events and the prognosis of both type 1 and type 2 diabetes. A treating health care professional can utilize information of the patient's physiologic well-being to make more informed decisions on a treatment plan if the physician has information of the patient's status at or near the time when glucose readings were taken. For example, information related to a hypoglycemic episode or event—“a feeling of hypoglycemia”—such as the type of event, time and date of the event, length of the episode, etc., which can then be compared to a blood glucose (BG) graph, would benefit diabetes management for the person with diabetes and the treating health care professional. Many hypoglycemic events go unrecorded, and often times the person with diabetes will treat the event without properly testing their blood glucose levels. Insight into these physiological events can provide a greater understanding of the frequency and/or severity of the events, and allow for more accurate treatment of the events when they do occur.
In the embodiment shown in
In an embodiment, after a user places a fluid sample (e.g., blood) on a test sensor (e.g., test sensor 70 of
The user may then press buttons 106a, 106b, or some other input element, to mark the reading accordingly based on whether the reading was taken when the user was happy, content or sad. In another embodiment, the user enters his/her emotional state prior to placing the fluid sample on the test sensor. It is contemplated that the user may mark the reading by input elements other than the previously described buttons 106a, 106b. Such input elements may include, but are not limited to, a touch screen, a single button, a dial, a toggle switch, preset times in the meter, and auto mark. In other optional configurations, an “autologging feature” can be provided that presents users with user-selectable options on a display of a testing system. The user is prompted to input information relating to the data that corresponds to the appropriate user-selectable option. An exemplary “autologging feature” is set forth in commonly owned U.S. patent application Ser. No. 12/156,043, which was filed on May 29, 2008, and is incorporated herein by reference in its entirety.
In an embodiment, no iconic markers are initially displayed via the display 102 before, during, or after the glucose reading is taken. In this embodiment, when the user first presses the arrow button 106a, the happy face iconic marker 108a appears on the display 102, as shown in
In another embodiment, the user may be prompted to enter his or her current state. As shown in
Upon the meter 100 displaying the desired marker, the user may select and confirm it by, for example, pressing the select button 106b or letting a predetermined amount of time pass whereby the highlighted iconic marker is automatically selected. As shown in
In either of the above descriptions, the selected iconic marker 108a, 108b, or 108c is preferably recorded and stored in the meter's memory along with the information pertaining to the particular reading of the fluid sample that the marker is associated with. The user may then go back at a later time to review and compare glucose readings, whereby one or more of the glucose readings would automatically display the corresponding iconic marker that the user had input for the readings.
In the embodiment shown in
In the embodiment shown in
Prior to, during, or after taking a blood glucose reading, the user may press buttons 106a, 106b, or some other input element, to mark the reading accordingly based on whether the reading was taken around the time when the user was experiencing physiological and/or emotional symptoms indicative of an event or disorder that may affect the analyte concentration reading. For example, the iconic markers 108d-i of
As another optional configuration, the meter can present the user with the option of whether to enter emotional state information, physiological state information, or information related to another state. For example,
Other iconic markers may additionally/alternatively be used to represent an emotional state of the user including, not limited to, the iconic markers shown in
Each of the iconic markers 108 shown in the drawings is in the form of a facial expression corresponding to the respective state being represented by that iconic marker 108. In some embodiments, the iconic markers 108 may be displayed along with a corresponding subheading. In some embodiments, the iconic markers 108 may be accompanied by sound effects or music. In some embodiments, each of the iconic markers 108 is animated corresponding to the respective state being represented by that iconic marker 108.
Other iconic markers may additionally/alternatively be used to represent a physiological state of the user. By way of example, other physiological signs common to a hypoglycemic event that may be marked with iconic markers include, for example, dizziness, nervousness, hungriness, paleness, and clumsiness. Other physiological signs common to a hyperglycemic event that may be marked with iconic markers include, for example, thirstiness, skin infections, and blurred vision.
It is also contemplated that emotional states and moods (and corresponding descriptive iconic markers) other than those described above may be employed by the meter and selectable by the user. Such emotional states and moods include, but are not limited to, the user being excited, fascinated, relaxed, stressed, annoyed, anxious, disappointed, jealous, tired and the like. It should also be noted that textual descriptions, as opposed to iconic markers, of the various emotional states may be displayed to the user, whereby the user simply selects which emotional state is textually displayed on the display without departing from the inventive subject matter described herein.
It is also contemplated that more than one emotional state may be presented to the user, and thus selected by the user, whereby the multiple emotional states are mapped to the particular fluid sample that is received and analyzed by the meter. In particular, upon receiving the fluid sample, the meter 100 may allow the user to select two or more iconic markers, each of which represents different emotional states. For example, the meter 100 may be configured to display a first iconic marker which corresponds to sadness as well as a second iconic marker which corresponds to jealousy when the fluid sample is received. Both emotional states (with or without the corresponding iconic markers) are then mapped to that fluid sample and stored in the meter's memory.
According to some embodiments, the device contains electrochemical test sensors that are used to determine concentrations of at least one analyte in a fluid. Analytes that may be determined using the device include, for example, glucose, lipid profiles (e.g., cholesterol, triglycerides, LDL and HDL), microalbumin, hemoglobin AlC, fructose, lactate, or bilirubin. The present disclosure is not limited, however, to devices for determining these specific analytes, and it is contemplated that other analyte concentrations may be determined. The analytes may be in, for example, a whole blood sample, a blood serum sample, a blood plasma sample, other body fluids like ISF (interstitial fluid) and/or urine. While the remainder of the disclosure herein is directed towards a display of iconic markers for use in glucose meters, it is to be understood that it may be implemented in meters used for determining other analytes.
According to one embodiment, the test sensors are used with self-monitoring blood glucose devices. The test sensors are typically provided with a capillary channel that extends from the front or testing end of the sensors to biosensing or reagent material borne by the sensor. When the testing end of the sensor is placed into fluid (e.g., blood that is accumulated on a person's finger after the finger has been pricked with a needle), a portion of the fluid is drawn into the capillary channel by capillary action. The fluid then chemically reacts with the reagent material in the sensor so that an electrical signal indicative of the analyte (e.g., glucose) level in the fluid being tested is supplied and subsequently transmitted to an electrical assembly. It should be noted that concepts of the present disclosure may also be used with continuous glucose monitoring (CGM) devices.
Reagent material that may be used to determine the glucose concentration includes, in one non-limiting example, glucose oxidase. It is contemplated, however, that other reagent material may be used to determine the glucose concentration such as glucose dehydrogenase. It is further contemplated that other reagent materials may be used to assist in determining glucose such as, for example, pyrrolo-quinoline quinone glucose dehydrogenase and potassium ferricyanide. The selected reagent may influence factors such as, for example, the amount of fluid needed and the length of time needed to perform the testing to determine the analyte concentration.
If an analyte other than glucose is being tested, different reagent material may be required. For example, non-limiting reagent material that may be used include lactate oxidase, cholesterol oxidase, alcohol oxidase (e.g., methanol oxidase), d-aminoacid oxidase and choline oxidase.
One non-limiting example of a test sensor is shown in
In the embodiment of
The computer 310 preferably runs on software which allows it to communicate with the meter 100 and thereby receive, process and display the information stored in the meter. In an embodiment, the software allows the computer 310 to organize and display the analyte concentration information with the corresponding iconic mark(s) for all or one or more selected fluid sample readings in a table and/or in graphical form. In an embodiment, the computer 310 displays the time and date of the readings along with the blood-glucose result and corresponding selected iconic mark(s) to inform the physician when the readings were taken. It is contemplated in an embodiment that the displayed information from the computer does not include the iconic markers themselves, but only textual information of the user's emotional state(s). In other words, the physician may be shown a particular glucose reading along with the word “sad”. Of course, a combination of textual emotional state information with the corresponding iconic mark is contemplated (e.g. text of “sad” along with a sad face).
In the above embodiments, one or more of the iconic markers may visually depict a respective emotional state of the user. Likewise, one or more of the plurality of iconic markers may visually depict a respective physiological state of the user. Optionally, displaying the iconic markers may include animating one or more of the displayed iconic markers in a manner corresponding to the respective state being represented by the iconic marker. As a further option, each of the iconic markers is presented as a facial expression corresponding to the respective state being represented by the iconic marker. The method of
In another embodiment, one or more concepts of the present disclosure are incorporated into a continuous glucose monitoring (CGM) system. An exemplary CGM system is the Guardian® Real-Time continuous glucose monitoring system, manufactured by Bayer HealthCare, LLC, of Tarrytown, N.Y. An exemplary CGM system is also depicted and described in U.S. Patent Application Publication No. 2006/0219576 A1, to Arvind N. Jina, which is incorporated herein by reference in its entirety. In one embodiment, a method of determining a concentration of an analyte in a fluid sample with a CGM system may begin by taking one or more fluid samples and analyzing at least one of the fluid samples to determine the analyte concentration of that fluid sample. The analyte concentration may be conveyed to the user. The device or system then receives information from the user that may affect the analyte concentration reading. This information may be related, for example, to physiological and/or emotional states of the user at or around the time of taking the reading. For instance, the device or system may display an array of iconic markers on a display, wherein each iconic marker corresponds to a particular physiological state and/or a particular emotional state. The user may select one of the displayed iconic markers, or chose another iconic marker, based on the particular state experienced by the user. The device or system receives this information and stores that information in a memory. The device or system may then process and map the user's selection with the time that the fluid sample was received and/or with the analyte concentration information.
In some embodiments, the device may be configured to display an icon, text, or other graphical information to the user in response to the user inputting emotional marker information. The displayed information can be in direct correlation to the emotional state of the user at the time that the user inputs his or her emotional state into the device. For instance, the device may be configured to display downloadable jokes, inspiring quotes, passages, funny pictures or other graphics in response to the user inputting that he or she is feeling sad or depressed. In another instance, the device may display a “CONGRATULATIONS!” if the device reading shows the user's blood-glucose level is within a normal range. This feature allows the device to be interactive with the user and thus provides a personal touch so that the user may feel more comfortable using the device.
While the invention is susceptible to various modifications and alternative forms, specific embodiments and methods thereof have been shown by way of example in the drawings and are described in detail herein. It should be understood, however, that it is not intended to limit the invention to the particular forms or methods disclosed, but, to the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
This application claims the benefit of and priority to U.S. Provisional Patent Application No. 61/233,437, filed on Aug. 12, 2009, which is incorporated herein by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
61233437 | Aug 2009 | US |